CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 125 enrolled
Drug / intervention
[18F]AV-1451 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04080544
NCT04080544Phase 2Completed
CompareCT.gov

Cause or Effect: Untangling the Relationship With Amyloid and Tau Deposits to Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study

Neil M Rofsky, MD, MHA·interventional·Posted Sep 6, 2019·Updated Sep 28, 2023

In Brief

A Phase 2 clinical trial evaluating [18F]AV-1451 and Positron Emission Tomography for Alzheimer Disease and Cognitive Decline. Completed, enrolled 125 participants across 1 site.

Detailed Summary

The investigators will conduct tau positron emission tomography (PET) scans on 125 adults using the radiopharmaceutical Flortaucipir F18 (\[18F\]AV-1451). This will allow the investigators to determine tau deposition across adults of different ages and assess the relationship of current tau burden to cognitive function and amyloid deposition collected over the previous 10-year interval.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease, Cognitive Decline
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 6, 2019
Enrollment StartJan 15, 2019
Primary CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 6.8 years ago

Interventions

[18F]AV-1451drug

The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of \[18F\]AV-1451.

Positron Emission Tomographyprocedure

Approximately 80 minutes after injection subjects will be placed in the UTSW PET/CT scanner for a 20-minute brain scan.